NorthStar Medical Radioisotopes LLC, a commercial-stage nuclear medicine company focused on advancing patient care by providing diagnostic and therapeutic radioisotopes, novel radiopharmaceuticals, and customized radiopharmaceutical development services, announced that it has achieved a major milestone in its efforts to deliver commercial-scale production of the scarce therapeutic radioisotope actinium-225 (Ac-225).
A custom-built IBA RhodotronTT 300-HE (high energy) electron beam accelerator has been delivered to NorthStar’s new Ac-225 production facility in Beloit and installed in a specially designed building. This state-of-the-art facility will be dedicated exclusively to the production of non-carrier added (n.c.a.) Ac-225 and is part of NorthStar’s expansion plan to ensure scalable, reliable, and environmentally preferable production of Ac-225 for treatment of patients with cancer and other serious diseases.
NorthStar is positioned to be the first commercial-scale producer of the therapeutic radioisotopes Ac-225 and Cu-67. The electron accelerator technology will produce high purity, non-carrier added (n.c.a.) Ac-225 that is free of long-lived radioactive byproducts associated with other production methods, which pose regulatory and waste management challenges for hospitals, health systems, and other health care institutions.
